NASDAQ: MTRIMentari Therapeutics Inc Stock
$12.20-3.80 (-23.75%)
Updated Nov 10, 2026
MTRI Price
$12.20
Fair Value Price
N/A
Market Cap
$6.70M
52 Week Low
$5.75
52 Week High
$23.30
P/E
-0.39x
P/B
-5.59x
P/S
9.07x
PEG
N/A
Dividend Yield
N/A
Revenue
$820.19k
Earnings
-$13.16M
Gross Margin
22.5%
Operating Margin
-1,603.78%
Profit Margin
-1,657.7%
Debt to Equity
-2.09
Operating Cash Flow
-$8M
Beta
1.17
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
MTRI Overview
InMed Pharmaceuticals Incorporated develops cannabinoid-based therapies. Its pipeline includes INM-755, a cannabinol topical cream in a second Phase I clinical trial for the treatment of Epidermolysis Bullosa, INM-088, in preclinical studies for the treatment of glaucoma, and INM-405 for the treatment of pain. It is also developing IntegraSyn, an integrated biosynthesis-based manufacturing process for synthesizing pharmaceutical-grade cannabinoids. InMed Pharmaceuticals was incorporated in 1981 and is headquartered in Vancouver, British Columbia, Canada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MTRI's potential to beat the market
- MTRI doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
MTRI
RankedUnranked of 450
RankedUnranked of 450
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $15.83 | A | |
| $916.06 | A | |
| $424.00 | A |
Be the first to know about important MTRI news, forecast changes, insider trades & much more!
MTRI News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MTRI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MTRI is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MTRI is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
MTRI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more MTRI due diligence checks available for Premium users.
Valuation
MTRI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.39x
Industry
17.34x
Market
41.12x
MTRI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-5.59x
Industry
5.28x
MTRI's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.3M
Profit Margin
0%
MTRI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
MTRI's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.3M
Liabilities
$2.5M
Debt to equity
-2.09
MTRI's short-term liabilities ($2.51M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MTRI's short-term assets ($1.26M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MTRI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
MTRI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.1M
Investing
$2.4k
Financing
$40.0k
MTRI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MTRI vs Biotech Stocks
Mentari Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.